AstraZeneca seeks FDA approval for Tagrisso-savolitinib lung cancer treatment
AZN•AstraZeneca submitted a US FDA application for Tagrisso with savolitinib to treat advanced lung cancer with MET overexpression or amplification after EGFR-targeted therapy. In the Phase III SAFFRON trial, the combination reduced the risk of death by 32% versus chemotherapy.
1. FDA application
AstraZeneca submitted a US FDA application for Tagrisso with savolitinib in advanced lung cancer with MET overexpression or amplification following EGFR-targeted therapy. The combination reduced the risk of death by 32% versus chemotherapy in the Phase III SAFFRON trial.
